Bulk Crystals,Ce Content,Content Of Melt,Crystal Field,Crystallographic Positions,Epitaxial,Epitaxial Layer,Information Deficit,Infrared Spectroscopy,Ionic Structure ...
Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...
News headlines Vertex Pharmaceuticals (VRTX) faces mixed performance as it prepares for a highly anticipated earnings release. While long-term revenue growth remains strong at 14.4% annually, recent ...
Shares of Vertex Pharmaceuticals Inc. rose 6.92% to $463.13 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.30% to 6,849.72 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback